Milwaukee Bucks star Giannis Antetokounmpo has become a shareholder in Kalshi, a major prediction market with a wide array of sports trading opportunities. Antetokounmpo announced the partnership ...
From the Department of Bizarre Anomalies: Microsoft has suppressed an unexplained anomaly on its network that was routing traffic destined to example.com—a domain reserved for testing purposes—to a ...
Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
LEAST 115 PEOPLE SINCE SEPTEMBER. THE UNITED STATES HAS FORMALLY LEFT THE WORLD HEALTH ORGANIZATION. THE W.H.O. SAYS MEMBERS OF ITS EXECUTIVE BOARD WILL NOW TALK ABOUT HOW TO HANDLE THE U.S.
California Gov. Gavin Newsom (D) announced just one day after the U.S. officially withdrew from the World Health Organization (WHO) that his state would become the first to join the organization’s ...
SACRAMENTO, Calif. (FOX 5/KUSI) — As the Trump administration moves to withdraw the United States from the World Health Organization (WHO), the state of California is taking a different approach to ...
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
Abstract: This paper studies the estimation of dynamic route choice behavior of drivers with incomplete fixed location-based sensor data, such as radio frequency identification (RFID) data. Unlike ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...